Roivant Sciences Ltd. and Pfizer Inc. officially launched Priovant Therapeutics on 28 June to develop Pfizer’s TYK2/JAK1 inhibitor brepocitinib, but the companies had been working together since September 2021 on plans for advancing the oral drug, initially for the treatment of dermatomyositis and system lupus erythematosus (SLE) and eventually for additional autoimmune diseases with high morbidity and mortality and limited treatment options.
Roivant CEO Matt Gline described the agreement with Pfizer as “a capital-efficient deal for us” during the company’s same-day call...